{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T03:00:04Z","timestamp":1782529204146,"version":"3.54.5"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s40262-021-01096-w","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T05:02:36Z","timestamp":1638939756000},"page":"577-587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol\/Norethindrone Acetate in Women with Uterine Fibroids"],"prefix":"10.1007","volume":"61","clinical-trial-number":[{"clinical-trial-number":"nct01620528","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01760954","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01931670","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02143713","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02654054","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02691494","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct0295494","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2730-6988","authenticated-orcid":false,"given":"Denise","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4015-7451","authenticated-orcid":false,"given":"Insa","family":"Winzenborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4898-8575","authenticated-orcid":false,"given":"Jacob","family":"Degner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3065-768X","authenticated-orcid":false,"given":"Nael M.","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3938-3040","authenticated-orcid":false,"given":"Peter","family":"Noertersheuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0147-8933","authenticated-orcid":false,"given":"Mohamad","family":"Shebley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,8]]},"reference":[{"issue":"5","key":"1096_CR1","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1210\/jc.2016-3845","volume":"102","author":"J Ng","year":"2017","unstructured":"Ng J, Chwalisz K, Carter DC, Klein CE. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J Clin Endocrinol Metab. 2017;102(5):1683\u201391.","journal-title":"J Clin Endocrinol Metab"},{"key":"1096_CR2","unstructured":"Orilissa\u2122 (elagolix) [United States package insert]. North Chicago: AbbVie Inc.; 2018."},{"key":"1096_CR3","unstructured":"Oriahnn\u2122 (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules) [United States package insert]. North Chicago: AbbVie Inc.; 2020."},{"issue":"2","key":"1096_CR4","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/0002-9378(92)91706-G","volume":"166","author":"RL Barbieri","year":"1992","unstructured":"Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol. 1992;166(2):740\u20135.","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"1096_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/GCO.0b013e32833b35a7","volume":"22","author":"ES Surrey","year":"2010","unstructured":"Surrey ES. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show? Curr Opin Obstet Gynecol. 2010;22(4):283\u20138.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"10","key":"1096_CR6","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s40262-018-0629-6","volume":"57","author":"I Winzenborg","year":"2018","unstructured":"Winzenborg I, Nader A, Polepally AR, Liu M, Degner J, Klein CE, et al. Population pharmacokinetics of elagolix in healthy women and women with endometriosis. Clin Pharmacokinet. 2018;57(10):1295\u2013306.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1096_CR7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1056\/NEJMoa1904351","volume":"382","author":"WD Schlaff","year":"2020","unstructured":"Schlaff WD, Ackerman RT, Al-Hendy A, Archer DF, Barnhart KT, Bradley LD, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med. 2020;382(4):328\u201340.","journal-title":"N Engl J Med"},{"issue":"6","key":"1096_CR8","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1097\/AOG.0000000000003869","volume":"135","author":"JA Simon","year":"2020","unstructured":"Simon JA, Al-Hendy A, Archer DF, Barnhart KT, Bradley LD, Carr BR, et al. Elagolix treatment for up to 12 months in women with heavy menstrual bleeding and uterine leiomyomas. Obstet Gynecol. 2020;135(6):1313\u201326.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"1096_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1056\/NEJMoa1700089","volume":"377","author":"HS Taylor","year":"2017","unstructured":"Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377(1):28\u201340.","journal-title":"N Engl J Med"},{"issue":"8","key":"1096_CR10","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/cpdd.640","volume":"8","author":"J Ng","year":"2019","unstructured":"Ng J, Duan WR, Marbury T, Schmidt JM, Klein CE. Elagolix pharmacokinetic profiles in women with renal or hepatic impairment. Clin Pharmacol Drug Dev. 2019;8(8):1053\u201361.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"3","key":"1096_CR11","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40262-019-00840-7","volume":"59","author":"M Shebley","year":"2020","unstructured":"Shebley M, Polepally AR, Nader A, Ng JW, Winzenborg I, Klein CE, et al. Clinical pharmacology of elagolix: an oral gonadotropin-releasing hormone receptor antagonist for endometriosis. Clin Pharmacokinet. 2020;59(3):297\u2013309.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"1096_CR12","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/jcph.1689","volume":"60","author":"AR Polepally","year":"2020","unstructured":"Polepally AR, Ng JW, Salem AH, Dufek MB, Parikh A, Carter DC, et al. Assessment of clinical drug\u2013drug interactions of elagolix, a gonadotropin-releasing hormone receptor antagonist. J Clin Pharmacol. 2020;60(12):1606\u201316.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1096_CR13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2217\/pmt-2019-0010","volume":"9","author":"HS Taylor","year":"2019","unstructured":"Taylor HS, Dun EC, Chwalisz K. Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain. Pain Manag. 2019;9(5):497\u2013515.","journal-title":"Pain Manag"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01096-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-021-01096-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01096-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T02:47:24Z","timestamp":1648867644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-021-01096-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,8]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1096"],"URL":"https:\/\/doi.org\/10.1007\/s40262-021-01096-w","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,8]]},"assertion":[{"value":"16 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by AbbVie. AbbVie contributed to the study design, research, and interpretation of the data and the writing, review, and approval of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"DB, IW, ML, JD, NMM, PN, and MS are employees of AbbVie Inc. and may hold AbbVie stock and\/or stock options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The studies reported herein were conducted in accordance with the International Council for Harmonisation guidelines, applicable regulations, guidelines governing clinical study conduct, and the ethical principles that have their origin in the Declaration of Helsinki. Approval was granted by institutional review boards and independent ethics committees at participating institutions.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All individual participants signed an informed consent regarding the publishing of their data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), provided the trials are not part of an ongoing or planned regulatory submission.\u00a0This includes requests for clinical trial data for unlicensed products and indications. This clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing agreement. Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study design, analysis, and interpretation of the data. All authors participated in the drafting and revising of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}